View Author
patient treatment disease infant study growth preterm infants glucosidase distensibility effect group wall distensibility muscle preterm artery pompe disease rotterdam baseline 4 patients head circumference oxygen pressure pompe control subjects swets subscription service pulsatility change enzyme children rhaglu month dexa treatment gh treatment heart length knee-heel length crown-heel length weight table development level pvr /svr analysis serum result rabbit increase heart disease inhalation glycogen netherland placebo therapy control glucosidase activity patient groups hemodynamic 40 mg /kg subject enzyme replacement therapy rabbit milk protein period circumference pediatrics hypertension dexamethasone vessel igf-i production hemoglobin concentration 20 mg /kg variable number activity bronchopulmonary dysplasia lung disease hypertrophy storage placebo group
3 Most Recent Publications
|
A randomized, placebo-controlled GH trial in very preterm infants who were at risk for bronchopulmonary dysplasia and were treated with dexamethasone.
(Article)
Huysman, M.W. Hop, W.C.J. Cromme-Dijkhuis, A.H. Sauer, P.J.J. Hokken-Koelega, A.C.S. |
2005-10-01
|
|
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk
(Article)
Hout, J.M.P. van den Sibbles, B. Corven, E.J. van Hirtum, H. van Kamphoven, J.H.J. Ploeg, A.T. van der Hove, J. van Arts, W.F.M. Doorn, P.A. van Klerk, J.B. de Loonen, M.C.B. Vulto, A.G. Brakenhoff, J.P. Kroos, M.A. Hop, W.C.J. Winkel, L.P.F. Jong, G. de Cromme-Dijkhuis, A.H. Weisglas-Kuperus, N. Reuser, A.J.J. Boer, M. Smeitink, J.A. Diggelen, O.P. van Voort, E. van der |
2004-01-01
|
|
Pulmonary arterial wall distensibility assessed by intravascular ultrasound in children with congenital heart disease: an indicator for pulmonary vascular disease?
(Article)
Berger, R.M.F. Cromme-Dijkhuis, A.H. Hop, W.C.J. Kruit, M.N. Hess, J. |
2002-01-01
|
